Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools

Business Wire01-03

NEW YORK, January 03, 2024--(BUSINESS WIRE)--Madryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn"), a holder of approximately 4.2% of the outstanding ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2400984827?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-03 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2400984827","market":"us","top_or_hot":-1,"title":"Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools","media":"Business Wire","content":"<div>\n<p>NEW YORK, January 03, 2024--(BUSINESS WIRE)--Madryn Asset Management, LP (\"Madryn Asset Management\" and, collectively with its affiliates, \"Madryn\"), a holder of approximately 4.2% of the outstanding ...</p>\n\n<a href=\"https://finance.yahoo.com/news/proxy-advisory-firm-egan-jones-130000396.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-03 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/proxy-advisory-firm-egan-jones-130000396.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, January 03, 2024--(BUSINESS WIRE)--Madryn Asset Management, LP (\"Madryn Asset Management\" and, collectively with its affiliates, \"Madryn\"), a holder of approximately 4.2% of the outstanding ...</p>\n\n<a href=\"https://finance.yahoo.com/news/proxy-advisory-firm-egan-jones-130000396.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4124","symbol_name":"机动车零配件与设备","start_time":0,"source_url":"https://finance.yahoo.com/news/proxy-advisory-firm-egan-jones-130000396.html","article_id":"2400984827","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2400984827","pubTimestamp":1704286800,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NEW YORK, January 03, 2024----Madryn Asset Management, LP , a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc.  , today announced that Egan-Jones Proxy Services , an independent proxy advisory firm, has recommended shareholders vote AGAINST the proposed merger  with Standard BioTools Inc.   at the Company’s Special Meeting of Shareholders  on January 4, 2024.\"Egan-Jones views the proposed transaction to be untimely and inadvisable in terms of maximizing shareholder value.\". \"We believe that the proposed merger agreement was a result of an insufficient search process due to the presence of conflict[s] of interests, which we view as detrimental to the assessment of the true value of the Company.\". Madryn Urges SomaLogic Shareholders to Vote \"AGAINST\" the Proposed Merger at the Company’s January 4, 2024, Special Meeting. Madryn Asset Management is a leading alternative asset management firm that invests in innovative healthcare companies specializing in uniq","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4124":"机动车零配件与设备","BK4121":"生命科学工具和服务","SMP":"Standard Motor Products Inc","SLGC":"SomaLogic, Inc.","SLGCW":"SomaLogic, Inc. Warrant 2026/08/31 11.5C"},"translate_title":"代理咨询公司Egan-Jones建议SomaLogic股东投票反对与Standard BioTools的合并提议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMP":1,"SLGC":0.9,"SLGCW":0.9},"content_text":"NEW YORK, January 03, 2024--(BUSINESS WIRE)--Madryn Asset Management, LP (\"Madryn Asset Management\" and, collectively with its affiliates, \"Madryn\"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (\"SomaLogic\" or the \"Company\") (Nasdaq: SLGC), today announced that Egan-Jones Proxy Services (\"Egan-Jones\"), an independent proxy advisory firm, has recommended shareholders vote AGAINST the proposed merger (the \"Proposed Merger\" or \"Transaction\") with Standard BioTools Inc. (\"Standard BioTools\") (Nasdaq: LAB) at the Company’s Special Meeting of Shareholders (the \"Special Meeting\") on January 4, 2024.\nIn its report, Egan-Jones noted:1\n\n\"Egan-Jones views the proposed transaction to be untimely and inadvisable in terms of maximizing shareholder value.\"\n\n\n\"We believe that the proposed merger agreement was a result of an insufficient search process due to the presence of conflict[s] of interests, which we view as detrimental to the assessment of the true value of the Company.\"\n\n\n\"Assuming that the merger will be consummated, Eli Casdin and Casdin Capital, LLC (\"Casdin Capital\") will retain their valuable Series B Preferred Put-Right in the pro forma combined entity.\"\n\n\n\"…Mr. Casdin’s ties with certain members of the Transaction Committee makes the process’ integrity questionable.\"\n\n\n\"…the merger significantly undervalues the Company’s worth... We believe that there is a crucial discount to the premium and to the Company’s value as well.\"\n\n\n\"…SomaLogic is better off as a stand-alone company, in the absence of a significantly higher offer.\"\n\nAvinash Amin, Managing Partner of Madryn Asset Management, stated:\n\"Egan-Jones clearly recognizes that the Proposed Merger is inherently flawed and not in the best interests of SomaLogic or its shareholders. We are pleased that Egan-Jones has joined the chorus of shareholders who have publicly opposed the Transaction due to its numerous failings, including an inadequate process, poor governance and blatant undervaluation of SomaLogic. We urge our fellow shareholders to follow Egan-Jones’ independent recommendation and vote against this Transaction.\"\n***\nMadryn Urges SomaLogic Shareholders to Vote \"AGAINST\" the Proposed Merger at the Company’s January 4, 2024, Special Meeting\nVoting \"AGAINST\" the Proposed Merger Will Protect the Value of Shareholders’ Investment and Allow SomaLogic to Pursue Vastly Superior Alternatives\nVisit www.NoSomaLogicMerger.com for Additional Information\n***\nAbout Madryn Asset Management\nMadryn Asset Management is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies and services. The firm draws on its extensive and diverse experience spanning the investment management and healthcare industries and employs an independent research process based on original insights to target attractive economic opportunities that deliver strong risk-adjusted and absolute returns for its limited partners while creating long-term value in support of its portfolio companies.\nIMPORTANT ADDITIONAL INFORMATION\nMadryn Asset Management, Madryn Health Partners, LP, Madryn Health Partners (Cayman Master), LP, Madryn Health Advisors, LP, Madryn Health Advisors GP, LLC, Madryn Select Opportunities, LP, Madryn Select Advisors, LP, Madryn Select Advisors GP, LLC and Avinash Amin (collectively, the \"Participants\") are participants in the solicitation of proxies from the stockholders of SomaLogic in connection with the special meeting of stockholders (the \"Special Meeting\"). On December 18, 2023, the Participants filed with the U.S. Securities and Exchange Commission (the \"SEC\") their definitive proxy statement and accompanying GREEN Proxy Card in connection with their solicitation of proxies from the stockholders of SomaLogic for the Special Meeting. The definitive proxy statement and accompanying GREEN Proxy Card are first being disseminated to stockholders on December 22, 2023. MADRYN STRONGLY ADVISES ALL STOCKHOLDERS OF SOMALOGIC TO READ THE DEFINITIVE PROXY STATEMENT, THE ACCOMPANYING GREEN PROXY CARD AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY THE PARTICIPANTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ADDITIONAL INFORMATION RELATED TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS IN SOMALOGIC, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all SomaLogic stockholders and is, along with other relevant documents, publicly available at no charge on the SEC’s website at http://www.sec.gov/. In addition, beginning December 22, 2023, the Participants will provide copies of the definitive proxy statement without charge, when available, upon request. Requests for copies should be directed to Madryn Asset Management.\nDisclaimer\nThis material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. In addition, the discussions and opinions in this press release are for general information only, and are not intended to provide investment advice. All statements contained in this release that are not clearly historical in nature or that necessarily depend on future events are \"forward-looking statements,\" which are not guarantees of future performance or results, and the words \"anticipate,\" \"believe,\" \"expect,\" \"potential,\" \"could,\" \"opportunity,\" \"estimate,\" and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained in this press release that are not historical facts are based on current expectations, speak only as of the date of this press release and involve risks that may cause the actual results to be materially different. Certain information included in this material is based on data obtained from sources considered to be reliable. No representation is made with respect to the accuracy or completeness of such data, and any analyses provided to assist the recipient of this presentation in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should also not be viewed as factual and also should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and subject to revision without notice. Madryn disclaims any obligation to update the information herein and reserves the right to change any of its opinions expressed herein at any time as it deems appropriate. Past performance is not indicative of future results.\n1 Permission to quote Egan Jones was neither sought nor obtained. Emphases added.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240103270063/en/\nContacts\nJohn Ferguson / Joseph MillsSaratoga Proxy Consulting, 212-257-1311info@saratogaproxy.com Joe Germani / Ashley AreopagitaLongacre Square Partners, 646-386-0091Madryn@LongacreSquare.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2400984827"}